statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for NEO
 DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsEqual-Weight Feb 2022NeedhamMaintainsBuy Feb 2022Raymond JamesMaintainsOutperform
 View More Analyst Ratings for NEO...

Where NeoGenomics Stands With Analysts

NeoGenomics, Inc. (NASDAQ: NEO) (the Company), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31...

NeoGenomics Reports First Quarter 2024 Results

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately. Warren Stone has been promoted...

NeoGenomics Announces Senior Leadership Promotions

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its first quarter 2024 financial results on Tuesday, April 30, 2024. Company...

NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024

This is a signal that NEO's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

NeoGenomics (NEO, $15.39) Stochastic Oscillator left the overbought zone on April 01, 2024

When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Shares of NeoGenomics, Inc. (NASDAQ:NEO  Get Free Report) have earned a consensus rating of Moderate Buy from the eleven ratings firms that are covering the stock, Marketbeat...

Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) Price Target at $19.22

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, alongside research collaborators, will present key findings from 11 abstracts at the American Association for Cancer...

NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting

This price move could indicate a change in the trend, and may be a sell signal for investors...

NeoGenomics (NEO, $15.21) price exceeded its 50-day Moving Average on March 22, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

NeoGenomics (NEO, $15.54) price moved above its 50-day Moving Average on March 20, 2024

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Volume	875,937.00
52-Wk High	$21.22
52-Wk Low	$11.03

NEO Neogenomics Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals